Beta-hCG Test Reference Range Determination

Terminated

• Conditions: Healthy

• Registration Number: NCT03485313
• Lead Sponsor: Response Biomedical Corp.

Brief Summary

Prospective, single-centre study to determine the reference range (95th percentile) of human chorionic gonadotropin (hCG) levels in a healthy, non-pregnant, adult female population using the RAMP® Total β-hCG test.

Detailed Description

Human chorionic gonadotropin (hCG) is a glycoprotein hormone secreted by the placenta shortly after implantation of a fertilized ovum into the uterine wall and the rapid rise of blood hCG concentration after conception makes it an excellent marker for confirmation and monitoring of early pregnancy. As such, levels in the blood of non-pregnant premenopausal individuals are low, typically \< 5 mIU/mL (milli-International Unit per milliliter).

In terms of identifying a clinically significant range of expected hCG values as determined by the RAMP β-hCG test, a 95th percentile of a healthy, non-pregnant, adult female reference population \[upper reference limit (URL)\] shall be determined in this study.

Subjects who meet the inclusion and exclusion criteria, and give informed consent will be enrolled in this study. Because hCG levels in blood increase with age, the study population will be divided into two age groups: 18 to 40 years and \>40 years, with approximately 125 subjects per group.

One EDTA (ethylenediaminetetraacetic acid) blood sample will be collected from each subject via standard venipuncture. The maximum trial duration for each subject will be one visit/blood draw.

Study Timeline

• Study First Submitted: 2018-03-26
• Study First Submitted QC: 2018-03-26
• Study First Posted: 2018-04-02
• Study Start: 2018-04-25
• Primary Completion: 2018-07-18
• Study Completion: 2018-08-29
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-23
• Last Update Posted: 2019-01-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 137

Inclusion Criteria

1. Apparently healthy, non-pregnant females, of any race.
2. >18 years of age.
3. Willing to voluntarily agree to sign a consent form.

Exclusion Criteria

1. Current pregnancy, suspected pregnancy, or pregnancy within previous 12 months.

2. Currently lactating/nursing a child.

3. Current diagnosis of Gestational Trophoblastic Disease, Gestational Trophoblastic Tumor or Gestational Trophoblastic Neoplasia.

4. Current diagnosis of non-trophoblastic tumors.

5. Current diagnosis of cancer and/or has undergone immunotherapy in the previous 12 months.

6. Current diagnosis of a serious health condition that involves inpatient care or continuing treatment by a health care provider, such as:

   • Conditions or treatments that result in continuous or episodic incapacity (e.g. pneumonia, epilepsy).
   • Permanent or long-term conditions (e.g. HIV, Alzheimer's, severe stroke).
   • Conditions requiring multiple treatment/recovery cycles (e.g. kidney disease).

7. Hospitalization (for >24 hours) or major surgery within previous 3 months.

8. Unable, or unwilling, to provide required blood sample for testing.

9. Investigator believes subject is unsuitable for inclusion in the trial (i.e. has serious condition(s) or other reason(s) that could limit their ability to participate in the study; or impact the scientific integrity of the study).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measurement of blood hCG level.	baseline	Measurement of hCG in a single EDTA blood sample from healthy, non-pregnant adult female subjects using the RAMP Total β-hCG test.

Trial Locations

Locations (1)

Response Biomedical Corp.; 🇨🇦 Vancouver, British Columbia, Canada